Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05726292 · ClinicalTrials.gov registry record · Phase 2

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

A Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by University of Chicago.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
2
Study locations

NCT05726292 is a Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 90 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05726292, a Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
2
Study locations

Study Summary

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.

Conditions Studied

Prostate Cancer Prostate Adenocarcinoma

Interventions

  • PROCEDURE Radical Prostatectomy
  • DRUG Enzalutamide
  • OTHER Androgen Deprivation Therapy
  • DRUG Relacorilant
  • OTHER Placebo (Sugar Pill)

Study Locations (2)

Illinois

  • University of Chicago Comprehensive Cancer Center - Chicago

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-01-06
Est. Completion 2028-04-01
Phase Phase 2

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05726292

The ClinicalTrials.gov registry entry for NCT05726292 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (85% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Radical Prostatectomy is the first listed.

NCT05726292 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Texas.

Frequently Asked Questions

What is clinical trial NCT05726292 about?

NCT05726292 is a clinical study titled "A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer". Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prost...

What is the current status of trial NCT05726292?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-01-06. Estimated completion is 2028-04-01.

What conditions does trial NCT05726292 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma.

What interventions are being tested in trial NCT05726292?

The interventions under investigation include: Radical Prostatectomy (PROCEDURE), Enzalutamide (DRUG), Androgen Deprivation Therapy (OTHER), Relacorilant (DRUG), Placebo (Sugar Pill) (OTHER).

Who is sponsoring clinical trial NCT05726292?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05726292 being conducted?

This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Prostate Adenocarcinoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.